Abstract
The identification of novel signalling pathways in a tissue provides new avenues for pharmacological manipulation of tissue function. Where the pathway concerned is one that has been the subject of extensive research in another body system, progress towards new therapies can be rapid. The discovery that glutamate has functions in bone that share striking similarities with its role in synaptic neurotransmission opens the way to manipulate skeletal pathophysiology using modulators of glutamate release, uptake or receptor function. The purpose of this review is to describe the way that a role for glutamate as a signalling molecule in bone was discovered, to summarise the evidence for this role. In addition, it will identify points that are unresolved, to highlight areas where new research could provide significant advances. Furthermore, it will indicate how studies already performed but analysed without consideration of the non-neuronal functions of modulators of glutamate signalling, could contain information of significant value for the advance of therapeutic approaches to bone diseases.
Keywords: Glutamate Signalling, Bone, NEURONAL GLUTAMATE SIGNALLING, OSTEOBLASTSOSTEOBLASTS
Current Pharmaceutical Design
Title: Glutamate Signalling in Bone.
Volume: 7 Issue: 8
Author(s): T. M. Skerry and A. F. Taylor
Affiliation:
Keywords: Glutamate Signalling, Bone, NEURONAL GLUTAMATE SIGNALLING, OSTEOBLASTSOSTEOBLASTS
Abstract: The identification of novel signalling pathways in a tissue provides new avenues for pharmacological manipulation of tissue function. Where the pathway concerned is one that has been the subject of extensive research in another body system, progress towards new therapies can be rapid. The discovery that glutamate has functions in bone that share striking similarities with its role in synaptic neurotransmission opens the way to manipulate skeletal pathophysiology using modulators of glutamate release, uptake or receptor function. The purpose of this review is to describe the way that a role for glutamate as a signalling molecule in bone was discovered, to summarise the evidence for this role. In addition, it will identify points that are unresolved, to highlight areas where new research could provide significant advances. Furthermore, it will indicate how studies already performed but analysed without consideration of the non-neuronal functions of modulators of glutamate signalling, could contain information of significant value for the advance of therapeutic approaches to bone diseases.
Export Options
About this article
Cite this article as:
Skerry M. T. and Taylor F. A., Glutamate Signalling in Bone., Current Pharmaceutical Design 2001; 7 (8) . https://dx.doi.org/10.2174/1381612013397771
DOI https://dx.doi.org/10.2174/1381612013397771 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-Based Biomarkers in Large-Scale Screening for Neurodegenerative Diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes Mellitus: Advances in Diagnosis and Treatment driving by Precision Medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle
Current Pharmaceutical Design Reviewing Biochemical Implications of Normal and Mutated Huntingtin in Huntington’s Disease
Current Medicinal Chemistry Effective Connectivity Between the Orbitofrontal Cortex and the Precuneus Differentiates Major Psychiatric Disorders: Results from a Transdiagnostic Spectral DCM Study
CNS & Neurological Disorders - Drug Targets Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Glucocorticoid-Induced Hypertension and Tetrahydrobiopterin (BH4), a Common Cofactor for the Production of Vasoactive Molecules
Current Hypertension Reviews Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults
Current Alzheimer Research Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Medicinal Chemistry of A2A Adenosine Receptor Antagonists
Current Topics in Medicinal Chemistry Neural Pathways and Neuropeptides Mediate the Therapeutic Actions of DPP IV Inhibitors in Type-2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology PET Imaging of MRP1 Function in the Living Brain: Method Development and Future Perspectives
Current Topics in Medicinal Chemistry Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Genetics of Serotonin Receptors and Depression: State of the Art
Current Drug Targets Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research Highlighting the Protective or Degenerative Role of AMPK Activators in Dementia Experimental Models
CNS & Neurological Disorders - Drug Targets Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
Current Pharmaceutical Design Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases
Current Molecular Medicine